Curasight

Curasight invited to Jefferies Global Healthcare Conference in London

Källa: Cision
Positiv

Sammanfattning

Curasight har blivit inbjudet att delta i Jefferies Global Healthcare Conference. Ledningen kommer att träffa investerare och diskutera bolagets utvecklingsprogram och strategiska prioriteringar.

Analys

Inbjudan till en investerarkonferens indikerar ett visst intresse från Jefferies sida för Curasights utvecklingsprogram. Mötena ger en möjlighet att presentera bolagets portfölj, inklusive uTREAT och uTRACE, samt diskutera partnerskap. Fokus ligger på glioblastom och prostatacancerprogrammen.

Insikter

  • • Inbjudan kan tolkas som ett positivt tecken på intresse från finansmarknaden.
  • • Konferensen ger en plattform för att lyfta fram bolagets teknologier och kliniska program.
  • • Fokus på partnerskap kan leda till framtida samarbeten.
Fundamental påverkan
Neutral

Ingen direkt fundamental påverkan på bolagets verksamhet eller finanser.

Omfattning: 2/10Marginell påverkan
0 · Ingen påverkan10 · Avgörande påverkan

Poängen visar omfattning, inte förväntad kursrörelse.

Copenhagen, Denmark, 13 November 2026 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS), a clinical-stage radiopharmaceutical company developing uPAR-targeted radiopharmaceuticals for cancer therapy and diagnostic imaging, today announces that its management team has been invited to attend the Jefferies Global Healthcare Conference in London, taking place on 16–19 November 2026.

During the conference, Curasight management will hold scheduled one-to-one meetings with international healthcare investors and industry representatives to discuss the Company’s clinical development programs, strategic priorities and potential partnering opportunities.

The meetings will provide an opportunity to highlight Curasight’s differentiated uPAR-targeted portfolio, comprising uTREAT® for radioligand therapy and uTRACE® for PET imaging and diagnostics. Discussions will focus on the Company’s lead glioblastoma therapeutic program, its ongoing Phase 2 prostate cancer diagnostic program and the development of next-generation uPAR-targeting ligands designed to support radioligand therapy across multiple solid tumor indications.

About Curasight A/S

Curasight is a clinical-stage radiopharmaceutical company developing uPAR-targeted radiopharmaceuticals for cancer therapy and diagnostic imaging. uPAR is a cell-surface target associated with aggressive tumor biology and has been clinically characterized using PET imaging in more than 500 patients across nine clinical studies and eight tumor types.

Curasight’s portfolio comprises uTREAT® for radioligand therapy and uTRACE® for PET imaging and diagnostics. Its lead therapeutic program targets glioblastoma, while its prostate cancer diagnostic program is in Phase 2 and partnered with Curium. The Company is also advancing next-generation uPAR-targeting ligands designed for use with alpha- and beta-emitting radionuclides, supporting potential therapeutic applications across multiple solid tumors.

Öppna PDF